Centiva Capital’s Starling Oncology STLN Stock Holding History

Centiva Capital’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-12,500	Closed	-$21K	–	1107
2020 Q3	$21K	Buy	+12,500	New	+$130K	﹤0.01%	673

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Centiva Capital's STLN Position: Q2 2026 in Review

Centiva Capital sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 224,245 shares — an estimated $688K sold.

Centiva Capital first reported a position in STLN in Q2 2020 and held it in 5 quarters. The position peaked at $688K in Q1 2026. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

Centiva Capital reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
Centiva Capital sold 224,245 Starling Oncology shares in Q2 2026, an estimated $688K.
Centiva Capital first reported a position in Starling Oncology in Q2 2020 and held it in 5 quarters.
Centiva Capital's Starling Oncology position peaked at $688K in Q1 2026.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.